Early Adjuvant Treatment with Semaglutide After Sleeve Gastrectomy in Patients with Class II-III Obesity: A Prospective Non-Randomized Controlled Study

What Was Tested

This controlled clinical trial paper looks at Semaglutide.

This study aimed to investigate the association between early, short-term adjunctive semaglutide therapy and postoperative weight-loss outcomes after laparoscopic sleeve gastrectomy (LSG) in patients with class II-III obesity.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

In this prospective, non-randomized controlled clinical study, patients with class II-III obesity, defined as a body mass index (BMI) ≥ 35 kg/m² scheduled for LSG were enrolled.

Semaglutide was administered as adjunctive therapy in the treatment group from 1 to 6 months postoperatively, while the control group received LSG alone.

How the Study Was Run

The primary outcome was the percentage of total weight loss (%TWL) at 12 months after surgery.

The main secondary outcomes included the percentage of excess weight loss (%EWL) at 12 months, the %TWL and %EWL at 6 months, the distributions of %TWL and %EWL, and metabolic parameters.

Exploratory analyses were also performed for body composition parameters.

What Was Measured

The subject headings attached to it are Semaglutide, Weight Loss, Gastrectomy, Obesity, Morbid, Glucagon-Like Peptides, Body Mass Index and Laparoscopy.

Author keywords: Class II-III Obesity, Prospective non-randomized controlled study and Sleeve gastrectomy.

What This Means in Plain Language

This is a controlled clinical trial of Semaglutide.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Obesity surgery), a journal based in United States.

More context: the Semaglutide compound page, all human trials.